Clinical Trial Update: The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease [Phase 2]

View source ↗

Summary

This update reports completion of a Phase 2 study evaluating Nefecon in patients with Primary IgA Nephropathy at risk of progressing to end-stage renal disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• Nefecon (nefecon)

Snippet

Sponsor: Calliditas Therapeutics AB | Conditions: Primary IgA Nephropathy | Phase 2 | Status: COMPLETED